ClinicalTrials.gg
CompletedNCT04060173Updated Feb 12, 2020

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

A Phase 1 interventional study of ABP-671 and Placebo in Hyperuricemia and Gout, sponsored by Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Hyperuricemia with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Hyperuricemia · United States.

Enrollment
47th of 70
27 · median 39
Started
2019
with 5 others
Phase 1
17 of 75
none open now
Registered
47th of 75
by date

Among the 75 studies in Hyperuricemia with a site in United States, this one is the 47th largest by enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2019, is one of 17 in phase 1, and was the 47th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

6 of the 75 studies in Hyperuricemia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Hyperuricemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.

03

Conditions studied

  • Hyperuricemia
  • Gout

Browse trials for

Keywords

  • Gout
  • Hyperuricemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be medically documented as healthy and acceptable at screening.
  • Subjects must have serum uric acid level at screening ≥ 7.0 mg/dL for men, ≥ 6.0 mg/dL for women.
  • Subjects must have a (BMI) between 18.0 and 34.0 kg/m2 (inclusive).
  • Subjects must have a body weight of 50 kg or higher.
  • The subject agrees to abstain from alcohol consumption for 48 hours prior to dosing, for the duration of the in-house study period, and for 48 hours prior to each in-clinic follow up visit.
  • The subject is a nonsmoker.
  • Women must be non-pregnant and non-lactating, and either surgically sterile or for ≥ 12 months.
  • Men must be surgically sterile, abstinent or if engaged in sexual relations with a female partner of , the participant must be using a condom with spermicide from Screening and for a period of 30 days after the last dose of Study Drug. The Investigator will assess the adequacy of methods of on a case-by-case basis.
  • Subjects must have a complete blood count (CBC) and count within the normal range or considered not by the principal investigator.
  • Other than elevated serum uric acid, subjects must have normal blood chemistry or results considered not clinically significant by the investigator.
  • Subjects must have a normal urinalysis or results considered not clinically significant by the investigator including a normal protein/creatinine ratio per local lab reference ranges (≤ 200 mg/g) and a urine creatinine result that does not exceed 300 mg/dL. Any out of range values may be repeated per Investigator discretion.
  • Subjects must have a normal or results considered not clinically significant by the principal investigator.
  • Subjects must be able to comply with the study and follow-up procedures.
  • Subjects are able to understand the study procedures and risks involved and must provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.
  • Subjects who are positive for (HIV), surface antigen, and/or virus.
  • Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 3 weeks before Day 1 of study medication dosing.
  • Subjects who are positive for urine drug and alcohol screening tests.
  • Subjects who have undergone major surgery within 3 months prior to Day 1.
  • Women who are pregnant or breastfeeding.
  • Subjects who received any test article within 5 half-lives or 30 days, whichever is longer, prior to Day 1 study medication dosing.
  • Recent blood donation for more than 500 mL within 2 months of screening.
  • Abnormal including > 470 (F) and > 450 (M).
  • Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.
  • Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.
  • Prior exposure to ABP-671.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Treatment with ABP-671

    Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.

    Drug: ABP-671

  • Placebo comparator
    Treatment with placebo

    Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.

    Other: Placebo

Interventions

  • ABP-671 is an investigational drug

  • OtherPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Measured by the number of patients with AEs

    Time frame: 38 days

Secondary outcomes

  1. Maximum observed plasma concentration of ABP-671 (Cmax)

    Time frame: 2 weeks

  2. Area under time-concentration curve (AUC)

    Time frame: 2 weeks

  3. Time of maximum observed plasma concentration of ABP-671 (Tmax)

    Time frame: 2 weeks

  4. Volume of distribution (Vd)

    Time frame: 2 weeks

  5. Half life of ABP-671 (t1/2)

    Time frame: 2 weeks

  6. The effect of ABP-671 versus placebo on the percent change from baseline in serum uric acid

    Time frame: 24 days

  7. The effect of ABP-671 versus placebo on change in urine uric acid excretion

    Time frame: 24 days

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Dec 2019, 3 months.

Of 29 industry-sponsored phase 1 interventional studies under Hyperuricemia, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 31 studies reached it within 6 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2019
First posted
Aug 19, 2019
StartActual
Sep 5, 2019
Primary completionActual
Dec 29, 2019
CompletionActual
Feb 7, 2020
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04060173
Lead sponsor
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 19, 2019
Start date
Sep 5, 2019
Primary completion
Dec 29, 2019
Completion
Feb 7, 2020
Last update
Feb 12, 2020

Study contacts

Danielle Armas, MD
principal investigator · Celerion

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-671

Start the discussion